Scholar Rock Holding Corporation (SRRK)
| Market Cap | 406.00M |
| Revenue (ttm) | 33.19M |
| Net Income (ttm) | -134.50M |
| Shares Out | 51.99M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 215,223 |
| Open | 8.46 |
| Previous Close | 8.61 |
| Day's Range | 7.65 - 8.49 |
| 52-Week Range | 4.33 - 15.43 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 23.02 (+194.75%) |
| Earnings Date | Mar 7, 2023 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-P... [Read more]
Financial Performance
In 2022, SRRK's revenue was $33.19 million, an increase of 76.41% compared to the previous year's $18.82 million. Losses were -$134.50 million, 2.05% more than in 2021.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $23.02, which is an increase of 194.75% from the latest price.
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
CAMBRIDGE, Mass.
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
CAMBRIDGE, Mass.
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present Data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors, at SITC Annual Meeting.
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at WMS Congress and International Scientific Congress on Spinal Muscular Atrophy.
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock's Board of Directors as an independent director.
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.
Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?
The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t...
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced an e-poster presentation on the ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at ICNMD 2022.
How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%
The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t...
Why Scholar Rock Shares Are Trading Higher Today
Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (...